|Biotech Due Diligence||
Please continue reading below for a new feature that we are excited to roll out here at BiotechDueDiligence. Conceived and curated by biotech trader @23aloha this blog series captures the tweets that best capture the biotech / pharma conversation on Twitter. The conversations here include reaction to and analysis of key market events and trends, as well as observations that in some cases go on to influence biotech stock trading. Feel free to offer any comments as we roll out this new effort!
In this post I will highlight some of the AACR Late-breaker abstracts that I am watching for, mostly related to clinical trial results. The big trials tend to be saved for ASCO in June, but there should be some interesting data nonetheless.
Preview Part 1 (SNTA, ASTX, NVS, INFI)
Preview Part 2
Preview Part 3 (ARRY, ASTX)
Preview Part 4 (ASTX, ARQL, BPAX)
Your support is greatly appreciated